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the preparation of scientific publications, guidelines, lec-
tures, workshops etc. At the present time the Russian pro-
fessionals actively participate in international randomized
clinical trials but the experience of pharmacoeconomic and
outcome research is very limited. So in the nearest future it
is important to organize adequate economic trials to show
the advantages and the disadvantages of existing health-
care interventions. The independence of investigators may
be guaranteed by governmental funding of such trials
though participation of the pharmaceutical industry seems
to be more real in the present economic crisis.
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Previous research into the usefulness of cost-effectiveness
information in managed care has had a narrow scope.
This research has been limited to the level of importance
that managed care directors place on pharmacoeconomic
(PE) data, the types of studies that MCOs prefer to re-
view and the future use of this type of information. 
OBJECTIVES: The purpose of this study was to ascertain
1) the level of importance that PE information has on the
speed of formulary approval, 2) the relationship between
the cost of therapeutic agents and PE information, 3) the
relationship between the time of market entry/number of
competitor products and requirements for PE informa-
tion, and 4) the importance of PE information by thera-
peutic classification. 
METHODS: A telephone survey of 41 randomly selected
pharmacy directors and medical directors was conducted
to elicit their attitudes towards PE information. 
RESULTS: PE information was somewhat/very impor-
tant in influencing the speed of formulary pull-through in
51.2% of respondents. The majority of respondents felt
that PE information was not important when drug acqui-
sition cost was less than $100; however, its importance
increased as acquisition cost increased. Respondents felt
that the time of market entry influenced the level that
they placed on PE information. When there were no sim-
ilar agents on formulary 73.1% felt that PE data was
somewhat/very important, when there were ten similar
agents on formulary 48.8% of respondents felt that PE
information was somewhat not/not important. Respon-
dents indicated that the therapeutic areas of depression,
asthma, rheumatoid arthritis, pain control, and hyperten-
sion were areas where cost-effectiveness analysis would
be most useful. 
CONCLUSIONS: PE information is relevant to managed
care decision-making and it is influenced by the drug ac-
quisition cost, the number of competitor drugs on market
and the therapeutic area under consideration.
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OBJECTIVE: The purpose of the study was to determine
the potential savings to the Portuguese National Health
System if the utilization of generic medications increased.
METHODS: The total sales of the 100 brand names with
the highest sales to the Portuguese National Health Sys-
tem in 1997 were examined to determine which ones had
a generic equivalent on the market. These were then sub-
stituted in four different scenarios where the substitution
levels were 10%, 25%, 50%, and 100% and the total
sales after substitution was calculated for each scenario.
Finally, the potential savings were determined. 
RESULTS: Of the 100 brand names with the highest sales
to the Portuguese National Health System in 1997, 18
had generic equivalents on the market. When these were
substituted at a 10% level, the estimated savings were
833.037.000 PTE (3.2%). When the substitution levels
were 25%, the estimated savings were 2.082.592.000 PTE
(8.0%). When the substitution level was 50%, the esti-
mated savings were 4.165.185.000 PTE (16.0%). When
the substitution level was 100%, the estimated savings
were 8.330.370.000 PTE (32.0%). 
CONCLUSION: Our pharmacoeconomic analysis dem-
onstrated that the Portuguese National Health System
can save a significant amount of its pharmacy budget by
increasing the utilization of generic medications.
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OBJECTIVE: The aim of this study was to study the
present situation regarding perceptions, understanding
and attitude towards pharmacoeconomics in Norway
among employees within the pharmaceutical authorities
and the pharmaceutical industry, prior to the introduc-
tion of pharmacoeconomic guidelines. 
METHODS: Personal interviews of employees working
with medicines on various levels were conducted, 47
from the authorities and 47 from the industry. The inter-
view included questions regarding associations to various
pharmacoeconomic expressions and questions about atti-
tude towards within which areas that pharmacoeconomic
analyses could be of use and the extent to which pharma-
coeconomic analyses should be implemented. The quanti-
tative data was handled in the statistical programme
SPSS. Factor analysis was used to find correlation among
some of the attitude questions. 
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RESULTS: Both those interviewed from the authorities and
the industry had a reasonable understanding of most of the
terms used within the pharmacoeconomic area and possi-
ble reasons for the actuality of pharmacoeconomics. How-
ever they seemed to lack some insight into the details in-
volved. As for perceptions about the extent of use, the
factor analysis showed that both the industry and the au-
thorities were positive to the introduction of pharmacoeco-
nomic analyses in relation to various decision-making pro-
cesses. However, the authorities were significantly more
positive than the industry to such use (t test for Equality of
Means: p  0.001 [equal variances not assumed]). 
CONCLUSIONS: Those interviewed seemed to welcome a
more extensive use of pharmacoeconomic analyses. Their
level of perception and understanding of the subject is re-
garded as good, when acting as observers. However, if
those interviewed are to get involved in decision-making
on the basis of pharmacoeconomic analyses, these users
need more training to gain more in-depth knowledge.
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OBJECTIVES: The economic impact of prescribing was
studied in urban community of Delhi. 
METHODS: Information on drugs prescribed was col-
lected from 4901 prescriptions from patients exiting 126
pharmacies. A systematic random sample of every tenth
pharmacy in seven zones of Delhi was drawn. The ratio-
nality of prescription was categorized by an independent
physician into the following categories: 1) Rational: if the
drugs prescribed confirmed to the criteria of efficacy
safety, cost, and convenience for the diagnosis/symptoms
or if the drugs prescribed were thought to be efficacious
enough to treat the underlying condition but were not the
drug of first choice for the condition or the most cost-
effective alternative. 2) Irrational: if the drugs prescribed
were in no way beneficial to the patients management or if
there was some negative pharmacokinetic or pharmacody-
namic interaction or it was over prescribed, under pre-
scribed or prescribed in wrong dosage schedule. 3) Diffi-
cult to comment: where prescription information in terms
of diagnosis/symptoms complex was incomplete or where
alternative herbal drugs were prescribed. The cost of ratio-
nal drugs was deducted from the total cost of prescription. 
RESULTS: It was found that one-third of prescriptions fell
in the difficult to comment category. This classification of
prescriptions is important to be described especially in a
study in a third world country. The costs of rational drugs
in commonest disorders, namely, acute respiratory infec-
tion, pyrexia of unknown origin and diarrhea were Rs. 43,
9, and 30 as compared to actual cost (i.e., Rs 59, 40, and
36, respectively [1 US $  approx. Rs. 40]). The use of
commonest drugs, antibiotics were irrational in 56.6%
cases. The private practitioners as compared to public sec-
tor facility doctors prescribed expensive antibiotics such as
newer cephalosporins and quinolones more irrationally.
On an average the specialists prescribed 2.34 drugs as
compared to 2.08 by the general practitioners. 
CONCLUSIONS: Irrational prescribing of drugs is com-
mon among the private practitioners in the urban settings
in Delhi. Such practice needs to be curbed. There appears
to be a great need for education and training of prescrib-
ers to minimize the irrational prescribing in developing
countries for the benefit of the poor people.
